| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Taub Center for Alzheimer’s Disease Research, the Gertrude H. Sergievsky Center (Drs. Romas, Tang, and Mayeux), the Departments of Medicine (Dr. Berglund), Neurology (Drs. Romas and Mayeux), and Psychiatry (Dr. Mayeux), and the Divisions of Epidemiology (Dr. Mayeux) and Biostatistics (Dr. Tang), School of Public Health, Columbia University, New York, NY.
Address correspondence and reprint requests to Dr. Richard Mayeux, Gertrude H. Sergievsky Center, 630 West 168th Street, Columbia University, New York, NY 10032.
BACKGROUND: Genetic variation at the APOE locus has a major influence on both plasma lipid levels and the risk of AD. The relationship between APOE genotype and plasma lipids may influence the risk of AD.
OBJECTIVE: In a community-based study of white, African American, and Caribbean Hispanic elderly in New York City, we investigated the relationship between plasma lipids and AD as well as the possible influence of APOE genotype on this relationship.
METHODS: Total plasma cholesterol (TC), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride levels were investigated in a cross-sectional study of nondemented elderly and patients with AD and in a prospective study of incident AD. Analyses included APOE genotype, gender, ethnicity, body mass index, and other potential confounders such as a history of hypertension, smoking, aspirin use, previous stroke, or ischemic heart disease.
RESULTS: Compared with nondemented elderly, decreased TC level had a weak but significant inverse association with incident AD, independent of APOE genotype. No other lipoprotein fragment was associated with either prevalent or incident AD.
CONCLUSION: Our results suggest that no consistent relationship exists between APOE genotype, plasma lipoproteins, and AD.
This article has been cited by other articles:
|
|
 |
|
  E. van Exel, P. Eikelenboom, H. Comijs, M. Frolich, J. H. Smit, M. L. Stek, P. Scheltens, J. E. Eefsting, and R. G. J. Westendorp Vascular Factors and Markers of Inflammation in Offspring With a Parental History of Late-Onset Alzheimer Disease Arch Gen Psychiatry, November 1, 2009; 66(11): 1263 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Kennelly, B. A. Lawlor, and R. A. Kenny Review: Blood pressure and dementia -- a comprehensive review Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 241 - 260. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Singh-Manoux, D. Gimeno, M. Kivimaki, E. Brunner, and M. G. Marmot Low HDL Cholesterol Is a Risk Factor for Deficit and Decline in Memory in Midlife: The Whitehall II Study Arterioscler Thromb Vasc Biol, August 1, 2008; 28(8): 1556 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Scarmeas Invited Commentary: Lipoproteins and Dementia--Is It the Apolipoprotein A-I? Am. J. Epidemiol., May 1, 2007; 165(9): 993 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Solomon, I. Kareholt, T. Ngandu, B. Winblad, A. Nissinen, J. Tuomilehto, H. Soininen, and M. Kivipelto Serum cholesterol changes after midlife and late-life cognition: Twenty-one-year follow-up study Neurology, March 6, 2007; 68(10): 751 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Jasinska-Myga, G. Opala, C. G. Goetz, J. Tustanowski, S. Ochudlo, A. Gorzkowska, and J. Tyrpa Apolipoprotein E Gene Polymorphism, Total Plasma Cholesterol Level, and Parkinson Disease Dementia Arch Neurol, February 1, 2007; 64(2): 261 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hall, J. Murrell, A. Ogunniyi, M. Deeg, O. Baiyewu, S. Gao, O. Gureje, J. Dickens, R. Evans, V. Smith-Gamble, et al. Cholesterol, APOE genotype, and Alzheimer disease: An epidemiologic study of Nigerian Yoruba Neurology, January 24, 2006; 66(2): 223 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Li, J. B. Shofer, W. A. Kukull, E. R. Peskind, D. W. Tsuang, J.C.S. Breitner, W. McCormick, J. D. Bowen, L. Teri, G. D. Schellenberg, et al. Serum cholesterol and risk of Alzheimer disease: A community-based cohort study Neurology, October 11, 2005; 65(7): 1045 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Mielke, P. P. Zandi, M. Sjogren, D. Gustafson, S. Ostling, B. Steen, and I. Skoog High total cholesterol levels in late life associated with a reduced risk of dementia Neurology, May 24, 2005; 64(10): 1689 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Dufouil, F. Richard, N. Fievet, J. F. Dartigues, K. Ritchie, C. Tzourio, P. Amouyel, and A. Alperovitch APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study Neurology, May 10, 2005; 64(9): 1531 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Solfrizzi, F. Panza, A. M. Colacicco, A. D'Introno, C. Capurso, F. Torres, F. Grigoletto, S. Maggi, A. Del Parigi, E. M. Reiman, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia Neurology, November 23, 2004; 63(10): 1882 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Fagan, E. Christopher, J. W. Taylor, M. Parsadanian, M. Spinner, M. Watson, J. D. Fryer, S. Wahrle, K. R. Bales, S. M. Paul, et al. ApoAI Deficiency Results in Marked Reductions in Plasma Cholesterol But No Alterations in Amyloid-{beta} Pathology in a Mouse Model of Alzheimer's Disease-Like Cerebral Amyloidosis Am. J. Pathol., October 1, 2004; 165(4): 1413 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Evans, S. Hui, A. Perkins, D. K. Lahiri, J. Poirier, and M. R. Farlow Cholesterol and APOE genotype interact to influence Alzheimer disease progression Neurology, May 25, 2004; 62(10): 1869 - 1871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mayeux, L. S. Honig, M.-X. Tang, J. Manly, Y. Stern, N. Schupf, and P. D. Mehta Plasma A{beta}40 and A{beta}42 and Alzheimer's disease: Relation to age, mortality, and risk Neurology, November 11, 2003; 61(9): 1185 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.A. Pappolla, T.K. Bryant-Thomas, D. Herbert, J. Pacheco, M. Fabra Garcia, M. Manjon, X. Girones, T.L. Henry, E. Matsubara, D. Zambon, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology Neurology, July 22, 2003; 61(2): 199 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. S. Tan, S. Seshadri, A. Beiser, P. W. F. Wilson, D. P. Kiel, M. Tocco, R. B. D'Agostino, and P. A. Wolf Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease: The Framingham Study Arch Intern Med, May 12, 2003; 163(9): 1053 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Engelhart, M. I. Geerlings, A. Ruitenberg, J. C. van Swieten, A. Hofman, J. C.M. Witteman, and M. M.B. Breteler Diet and risk of dementia: Does fat matter?: The Rotterdam Study Neurology, December 24, 2002; 59(12): 1915 - 1921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kivipelto, E.-L. Helkala, M. P. Laakso, T. Hanninen, M. Hallikainen, K. Alhainen, S. Iivonen, A. Mannermaa, J. Tuomilehto, A. Nissinen, et al. Apolipoprotein E {epsilon}4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease Ann Intern Med, August 6, 2002; 137(3): 149 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Hajjar, J. Schumpert, V. Hirth, D. Wieland, and G. P. Eleazer The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2002; 57(7): M414 - 418. [Abstract] [Full Text]
|
|
|
|
 |
|
 V Solfrizzi, F Panza, A D'Introno, A M Colacicco, C Capurso, A M Basile, and A Capurso Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, June 1, 2002; 72(6): 732 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yaffe, E. Barrett-Connor, F. Lin, and D. Grady Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women Arch Neurol, March 1, 2002; 59(3): 378 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rockwood, S. Kirkland, D. B. Hogan, C. MacKnight, H. Merry, R. Verreault, C. Wolfson, and I. McDowell Use of Lipid-Lowering Agents, Indication Bias, and the Risk of Dementia in Community-Dwelling Elderly People Arch Neurol, February 1, 2002; 59(2): 223 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Reynish, S. Andrieu, F. Nourhashemi, and B. Vellas Nutritional Factors and Alzheimer's Disease J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2001; 56(11): M675 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Launer, L. R. White, H. Petrovitch, G. W. Ross, and J. D. Curb Cholesterol and neuropathologic markers of AD: A population-based autopsy study Neurology, October 23, 2001; 57(8): 1447 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kalmijn, D. Foley, L. White, C. M. Burchfiel, J. D. Curb, H. Petrovitch, G. W. Ross, R. J. Havlik, and L. J. Launer Metabolic Cardiovascular Syndrome and Risk of Dementia in Japanese-American Elderly Men : The Honolulu-Asia Aging Study Arterioscler Thromb Vasc Biol, October 1, 2000; 20(10): 2255 - 2260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Knittweis, W. A. McMullen, S. N. Romas, R. Mayeux, A. J. C. Slooter, A. Ruitenberg, C. M. van Duijn, M. M. B. Breteler, and H. C. Liu The effect of apoE on dementia is not through atherosclerosis: The Rotterdam Study Neurology, June 27, 2000; 54(12): 2356 - 2358. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
